In summary, the PACE-MDS study reported that 1.0 mg/kg luspatercept with up to 1.75 mg/kg titration is the appropriate starting dose for further studies in patients with MDS, that the drug is effective in patients with high endogenous EPO, regardless of prior ESA use, and that response was more frequent and robust in patients with RS ≥ 15% or SF3B1 mutations [46]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.